Heart Disease, Vasodilation
Conditions
Keywords
Renin angiotensin system, Apelin, Vasodilatation, Heart disease, Vascular biology
Brief summary
The apelin-APJ system is a relatively new discovery. It has generated interest in part due to it's apparent ability to counteract the renin-angiotensin system, which is frequently overactive in many cardiovascular disease. Apelin has the ability to cause blood vessels to relax, increasing their diameter and hence blood flow down the blood vessel. The researchers wish to investigate the hypothesis that an infusion of apelin will reduce the effects of angiotensin II, which is know to reduce the diameter of blood vessels.
Interventions
DRUGAngiotensin II
Infusion of up to 30picmol/ml angiotensin II will be infused and respondent vasoconstriction assessed.
Infusion of up to 480 picomol/ml of noradrenaline will be infused.
Sponsors
University of Edinburgh
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
* \> 18 years old * Healthy volunteers
Exclusion criteria
* Lack of informed consent * Age \< 18 years, * Current involvement in other research studies, * Systolic blood pressure \>190 mmHg or \<100 mmHg * Malignant arrhythmias * Renal or hepatic failure * Haemodynamically significant aortic stenosis * Severe or significant co morbidity * Women of childbearing potential. * Any regular medication * Previous history of any cardiovascular disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in angiotensin II mediated vasoconstriction | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| Changes in relevant neurohumoral hormones in response to apelin infusion | 12 months |
Countries
United Kingdom
Outcome results
None listed